Aripiprazole for schizophrenia: Systematic review

British Journal of Psychiatry

Volumn 189, Issue AUG., 2006, Pages 102-108

  El Sayeh, H G ^a,c   Morganti, C ^b   Adams, C E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c HARROGATE DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; RISPERIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANXIETY; CLINICAL PROTOCOL; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PIPERAZINES; PROLACTIN; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33747173804     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.189.2.102     Document Type: Review

References (22)

1. Adson, D., Bari, B., Bona, J., et al (2002) Abilify (Aripiprazole) Tablets. Medical Review. Part I. Rockville, MD: US Food and Drug Administration, http://www.fda.gov/cder/foi/nda/2002/21-436-Abilify.htm [date accessed 01/10/04].
2. Altobeck, P. (1989) Schizophrenia: a life-shortening disease. Schizophrenia Bulletin, 15, 81-89.
3. American Psychiatric Association Work Group on Schizophrenia (2004) Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161, 15-18.
4. Carson, W. H., Ali, M., Saha, A. R., et al (2000) A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Abstract: 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10-14, San Juan, Puerto Rico. Available on request from: Bristol-Myers Squibb Ltd Medical Information (tel: 0800 7311 736).
5. Carson, W. H., Pigott, T. A., Saha, A. R., et al (2002) Aripiprazole vs. placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology, 5 (suppl. 1), 187.
6. Clarke, M. & Oxman, A. D. (2003) Cochrane Reviewer's Handbook 4.2.0. Oxford: Cochrane Collaboration. http://www.cochrane.dk/cochrane/handbook/hbook. htm
7. Csernansky, J., Garbutt, J., Goff, D. C., et al (2002) In Dubitsky, G. M., Harris, R., Laughren, T., Hardeman, S. Abilify (Aripiprazole) Tablets, Medical Review, Part I. Rockville, MD: US Food and Drug Administration, http://www.fda.gov/cder/foi/nda/2002/21-436-Abilify.htm,1-50 [date accessed 01/10/04].
8. Daniel, D. G., Saha, A. R., Ingenito, G., et al (2000) Aripiprazole, a novel antipsychotic: overview of a phase II study result. International Journal of Neuropsychopharmacology, 3 (suppl. 1), 157.
9. Dubitsky, G., Harris, R. D., Laughren, T., et al (2002) Abilify (Aripiprazole) Tablets. Medical Review Part 4. Rockville, MD: US Food and Drug Administration. http://www.fda.gov/cder/foi/nda/2002/21-436-Abilify_ medr.P-4.pdf [date accessed 01/10/04].
10. El-Sayeh, H. G. & Morganti, C. (2004) Aripiprazole for schizophrenia (Cochrane Review). Cochrane Library, issue 2. Chichester: John Wiley & Sons.
11. Gelder, M., Lopez-Ibor Jr, J. J. & Andreason, N. C. (2000) Antipsychotic and anticholinergic drugs. In New Oxford Textbook of Psychiatry, Volume 2.
12. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmocology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health.
13. Higgins, J. P., Thompson, S. G., Deeks, J. J., et al (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557-560.
14. Kane, J., Carson, W., Kujawa, M., et al (2003) Aripiprarole vs perphenazine in treatment-resistant schizophrenia. Abstract: 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco, USA. Available on request from: Bristol-Myers Squibb Ltd Medical Information (tel: 0800 7311 736).
15. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
16. Kern, R. S., Cornblatt, B., Carson, W. H., et al (2001) An open-label comparison of the neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis (abstract). Schizophrenia Research, 1-2, 234.
17. Kujawa, M., Saha, A. R., Ingenito, G. G., et al (2002) Aripiprazole for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychophormacology, 5 (suppl. 1), 186.
18. McQuade, R. D., Jody, D. N., Kujawa, M. J., et el (2003) Long-term weight effects of aripiprazole vs olanzapine. Abstract: 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco, USA. Available on request from: Bristol-Myers Squibb Ltd Medical Information (tel: 0800 7311 736).
19. Moher, D., Schulz, K. F. & Altman, D. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA, 285, 1987-1991.
20. Office for National Statistics (2001) Age-Standardised Mortality Rates by Sex and Cause. London: Office for National Statistics. www.statistics.gov.uk/ StatBase/Expodata/Spreadsheets/D7739.xls
21. Potkin, S. G., Saha, A. R., Kujawa, M. J., et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 60, 681-690.
22. Rivas-Vasquez, R. A. (2003) Aripiprazole: a novel antipsychotic with dopamine-stabilising properties. Professional Psychology: Research and Practice, 34, 108-111.